Drug Enforcement Administration (DEA)

Rule Changes

Signed memorandum of agreement with CVS for future compliance

CVS Pharmacy agreed to pay $315 million to settle federal allegations that it illegally filled opioid and other controlled-substance prescriptions from October 2013 through December 2025. It then billed Medicare and other federal programs for many of those invalid prescriptions. CVS admitted no wrongdoing, and the allegations remain unproven.

Updated Oct 27

Money Moves

Led the investigation with the FBI and Homeland Security Investigations

After seven years as a federal fugitive, Colombian businessman Álvaro Pulido appeared in a Miami courtroom Tuesday and was ordered held in federal custody. He faces two indictments accusing him of laundering more than $2 billion stolen from Venezuelan government programs.

Updated Oct 14

Rule Changes

As of May 2026: Must run the hearing-driven process and issue any final scheduling rule

Trump's executive order instructing DOJ to fast-track marijuana's move to Schedule III immediately triggered a familiar split. Public health and industry groups cheered the potential research and tax impacts, while House Republicans organized opposition, urging Trump to keep marijuana in Schedule I.

Updated May 15

Rule Changes

As of May 2026: Issued the final rule placing 4-CMC in Schedule I under the CSA

4-CMC is one of those modern drug-market products built for speed: cheap, tweakable chemistry that can be sold as a "new" stimulant the moment the old one gets banned. On December 17, 2025, the U.S. finally snapped the trap shut—DEA's Schedule I controls for 4-CMC took effect nationwide.

Updated May 15